ATAHC Recall: Long-term outcomes following treatment of recently acquired hepatitis C virus infection

Date Commenced:
January 2012
Project Status
Ongoing
Expected Date of Completion:
June 2016
Project Supporters

St Vincent’s Hospital Research Foundation

Currently recruiting
No
image - Kirby Logo On White 86

About the Project

Rationale

Hepatitis C virus (HCV) infection is a public health problem however very little is known about the health of patients years following therapy, and whether HCV treatment at an early stage continues to be beneficial to people. The Australian Trial in Acute Hepatitis C (ATAHC) previously enrolled 163 subjects with recent (ie acute or early chronic) HCV infection between 2004 and 2008. Uptake of treatment was high, with 79% initiating therapy. Follow-up was maintained for up to 2 years post SVR with continued specimen and data collection, with 7 reinfections observed during this time. The study closed in 2007 and the original subjects are now an average of 5.6 years from initial infection. The ATAHC study demonstrated the successful recruitment, engagement and early follow-up of one of the largest international cohorts of individuals with AHC and established one of the most extensive serum, plasma and PBMC storage banks of AHC worldwide. Longitudinal follow-up at this point will allow for the first international, long-term assessment of clinical, social, behavioural, psychological and immunovirological outcomes. It will provide diagnostic data to translate into clinical practice guidelines for recent HCV infection treatment.

Aims
  1. To evaluate the effect of successful prior treatment of spontaneous clearance of recently acquired HCV infection on long-term quality of life, social functioning, injecting behaviour, mental health and liver health.
  2. To assess the incidence of HCV re-infection following prior treatment induced clearance or spontaneous clearance of recently acquired chronic HCV infection.
  3. To determine predictors of HCV re-infection following recently acquired HCV infection treatment.
  4. To determine frequency and predictors of new mixed and superinfections in ATAHC subjects with persistent HCV viraemia.
  5.  To add to a tissue repository of serum and PBMCs from well-characterised patients treated for recently acquired HCV infection to allow future examination of the role of other variables that may potentially impact on the prognosis and outcomes of early HCV treatment.
Design & Method

A single long-term follow up assessment of an established multi-centre, prospective longitudinal cohort study of patients for clinical, psychosocial, immunovirological outcomes 4 to 8 years after previous treatment for recently acquired hepatitis C virus infection.

Progress/Update

There are currently no patients enrolled. 

Project Members
image - Jason Grebely Replace
Senior Research Fellow (UNSW)
Ph +61 (2) 9385 0957
image - Dore
Professor and Program Head
Ph 02 9385 0900
image - Pip Marks
Clinical Trials Manager
Ph +61 (0)2 9385 0886
image - Img 5105 Cropped 3mb 2
Post Graduate Research Candidate
Ph +61 (0)2 9385 0230
image - Fracois Lamovry
Senior Research Officer
Ph +61 (0)2 9385 0900
image - Amanda Erratt
Clinical Project Coordinator
Ph +61 2 9385 0882
image - 1338781537 Austin1jpg
Mr Austin Butcher
Laboratory Coordinator
Other Investigators

A/Professor Margaret Hellard

Dr Joseph Doyle

Dr David Shaw

Project Collaborators: External

St Vincent’s Hospital, Sydney

The Alfred Hospital, Melbourne

Royal Adelaide Hospital, Adelaide

Project Research Area

Project Contacts

Related Projects